Navigation Links
SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
Date:7/29/2008

BELLEVUE, Wash., July 29 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (Amex: DDD) today announced plans to release second quarter 2008 financial results on Thursday, August 7, 2008, at 8:30 a.m. Eastern. Daniel O. Wilds, President and CEO of SCOLR Pharma, will host a conference call at 11:30 a.m. Eastern, to discuss the results.

Shareholders and other interested parties may participate in the conference call by dialing +1 888 680 0878 (domestic) or +1 617 213 4855 (international) and entering access code 26733631, a few minutes before 11:30 a.m. ET on August 7, 2008. The call will also be broadcast live on the Internet at http://www.streetevents.com, http://www.fulldisclosure.com or http://www.scolr.com.

A replay of the conference call will be accessible two hours after its completion through August 21, 2008, by dialing +1 888 286 8010 (domestic) or +1 617 801 6888 (international) and entering access code 55141034. The call will also be archived for 90 days at http://www.streetevents.com, http://www.fulldisclosure.com or http://www.scolr.com.

Based in Bellevue, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company. SCOLR Pharma's corporate objective is to combine its formulation expertise and its patented CDT platform to develop novel pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platform is based on multiple issued and pending patents and oth
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
2. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
3. China Biopharma, Inc. Announces New Plan of Operation
4. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
5. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
6. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
7. Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today
8. Cepheid Schedules Fiscal 2008 Second Quarter Financial Results Announcement and Webcast
9. Schering-Plough Schedules Conference Call and Webcast for 2008 Second Quarter Earnings
10. Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
11. ImaRx Schedules Release of First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... optimized Erk inhibitor molecule for development, thus achieving ... new class of potential cancer therapies. ... for therapeutic intervention in cancer. Recently approved compounds ... B-Raf and Mek inhibitors. Erk inhibitors may be ...
(Date:7/29/2015)... ... July 29, 2015 , ... Costello served as Lead Levee Design Engineering Manager ... Orange County, Texas area from future storm surge flooding, such as occurred in Hurricane ... levee alignment alternatives for providing protection, Costello also balanced socio-economic and environmental needs ...
(Date:7/28/2015)... 29, 2015 A ... rapidly developing and commercialising innovative medicines to transform ... Highly experienced management team; blue chip ... Mereo BioPharma Group Ltd ("Mereo"), a recently-formed speciality ... c. £76.5m), gross, from blue chip institutional investors and ...
(Date:7/28/2015)... YORK , July 28, 2015 People ... by hearing aids achieved significant and sometimes profound improvements ... cochlear implant devices, according to a new multicenter study ... In the study, described online ahead of print in ... medical centers and private clinics in the ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Preventing Storm Surge Flooding in Houston 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3
... Q4/07 Review Issued by Scimitar Equity Research, Inc., ... Inc.,(Scimitar) issues a review of Neurobiological Technologies, Inc. ... of Purpose:,VIPRINEX(TM) Could Restore Stroke Patients to Fuller ... NTII,s Achievement". This review is available at ...
... Merger, IRVINE, California, September 19 ... orthobiologics company, today announced that,Institutional Shareholder Services, ... the merger of IsoTis and Integra,LifeSciences Holdings ... For every M&A analysis, ISS reviews publicly ...
... new speakers will,grace the faculty of the "Pharma ... two weeks in New Jersey. The conference is,the ... Market,Forecasting executives; 200 from the top 25 companies ... Competition has never been fiercer to,launch successful products ...
Cached Biology Technology:Neurobiological Technologies, Inc. (Nasdaq: NTIID) 2IsoTis - Integra Merger 2IsoTis - Integra Merger 3IsoTis - Integra Merger 4IsoTis - Integra Merger 5New Competitive Intelligence Speakers Spark Interest in Pharmaceutical Conference on October 1-2 in NJ 2
(Date:6/25/2015)... CITY , June 25, 2015  Imagine a ... steps toward a healthier, happier life. That,s exactly what ... designed to do. The cutting-edge, portable health program provides ... real-life solutions to help improve your lifestyle and nutrition. ... awards dinner and gala Wednesday night, USANA,s THA was ...
(Date:6/24/2015)... -- This report provides market analysis of the Automatic ... contains an analysis of the drivers, challenges, and restraints ... the short, medium, and long term perspective landscapes. ... technology trends that currently, prevail in the market. It ... efficiently manage the increasing marine traffic and increasing importance ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... Despite current beliefs, sugar intake is not directly associated ... study in Gastroenterology , the official journal of ... progression of this serious form of liver disease. ... overweight men to compare the effects of high intakes ...
... found an association between lower socioeconomic status during childhood ... protein complexes at the end of chromosomes, that ultimately ... Published in Brain, Behavior and Immunity ... parents of lower socioeconomic status have shorter telomeres as ...
... disappearedwere home to dozens of species of grasses that could ... of flowers, and herds of roaming bison. For ... of Colorado Boulder has gotten a peek at another vitally ... tallgrass prairie home: the diverse assortment of microbes that thrived ...
Cached Biology News:Sugar intake is not directly related to liver disease 2Children of lower socioeconomic status grow up more susceptible to catching colds, Carnegie Mellon researchers find 2CU-Boulder-led team gets first look at diverse life below rare tallgrass prairies 2
... Adding an exciting new chapter ... GC leadership, Agilents 7890A GC ... to take your lab to ... and GC/MS performance, including advanced ...
... Pan-Caspase In Situ Assay Kit, Fluorescein is ... caspases in cells undergoing apoptosis. The kit ... use in diagnostic or therapeutic procedures. CHEMICON®s ... a novel approach to detect active caspases. ...
... concentrated jetSI 10 nM is available for ... brain as described in: Z. Hassani, G.-F. ... J.-P. Behr, and B.-A. Demeneix. Lipid-mediated siRNA ... the mouse brain at picomolar levels. J. ...
... Tissue Staining Kits are intended for localization ... histological and cytological specimens. These kits may ... by either R&D Systems or by other ... formation of the Avidin-Biotin Complex (ABC) with ...
Biology Products: